Table 2.

Walking distance and Expanded Disability Symptom Scale during triamcinolone acetonide treatment.

	All patients (n ¼ 31)	SPMS (n = 22)	PPMS (n = 9)
WD before TCA	194 m	168 m	257 m
(Mean [range])	[10–800 m]	[10–400 m]	[40–800 m]
WD after TCA	498 m	488 m	518 m
(Mean [range])	[15–2000 m]	[90–2000 m]	[15–1200 m]
Significance p	p < 0.001	p = 0.001	p = 0.046
EDSS before TCA (Mean±SD)	5.5 ± 0.9	5.5±0.9	5.4 ±1.0
EDSS after TCA (Mean±SD)	4.9 ± 1.0	4.9 ±0.9	4.8± 1.1
Significance p	p < 0.001	p = 0.001	p = 0.071
Number of TCA injections	3 inj.: 1 patient 6 inj.: 30 patients	6 inj.: 22 patients	3 inj.: 1 patient 6 inj.: 8 patients

Data are quoted as mean (±SD) [range], n, number of subjects; WD, walking distance; SPMS, secondary progressive MS; PPMS, primary progressive MS; p, statistical significance of differences between WD (respectively EDSS) after therapy in comparison with therapy start by Wilcoxon signed rank testing.